Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Cryo Cell International (CCEL) Dividends Paid - Common (2024 - 2025)

Cryo Cell International's Dividends Paid - Common history spans 2 years, with the latest figure at $1.2 million for Q2 2025.

Quarterly results put Dividends Paid - Common at $1.2 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Feb 2026 was $1.2 million (down 70.04% YoY), and the annual figure for FY2025 was $3.2 million, up 59.92%.
Dividends Paid - Common for Q2 2025 was $1.2 million at Cryo Cell International, down from $2.0 million in the prior quarter.
In the past five years, Dividends Paid - Common ranged from a high of $2.0 million in Q4 2024 to a low of $1.2 million in Q2 2025.